Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Change in Cash (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Change in Cash for 16 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 118.89% to $2.2 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$5.4 million, a 89.67% increase, with the full-year FY2025 number at -$35.0 million, down 96.01% from a year prior.
  • Change in Cash was $2.2 million for Q4 2025 at PharmaCyte Biotech, up from -$2.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $86.0 million in Q4 2021 to a low of -$17.5 million in Q3 2024.
  • A 5-year average of $584430.6 and a median of -$1.6 million in 2021 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: skyrocketed 5444.16% in 2021, then tumbled 1346.31% in 2023.
  • PharmaCyte Biotech's Change in Cash stood at $86.0 million in 2021, then plummeted by 106.12% to -$5.3 million in 2022, then skyrocketed by 76.5% to -$1.2 million in 2023, then tumbled by 853.32% to -$11.8 million in 2024, then soared by 118.89% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Change in Cash are $2.2 million (Q4 2025), -$2.0 million (Q3 2025), and -$1.2 million (Q2 2025).